Current research revealed that myricetin could block HCC cell cycle at G2/M phase to suppress HCC growth by downregulating the MARCH1/p38 MAPK/Stat3 signaling pathway. The gene discussed is MARCHF1; the disease is hepatocellular carcinoma.